Please login to the form below

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds

Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.

By Jennifer Blainey, Director, Hanover Health

By creating England’s first Women’s Health Strategy, the Government has signalled its intention to take seriously the healthcare needs of women and crucially, make ordinary women central in these discussions. If this strategy is to succeed it will need to ensure it does more than listen but delivers a plan that ensures 51% of the population is properly represented in clinical trials and service design. In a society which is so interconnected it is in everyone’s interests to have women’s health improved, not just for women themselves.

In the press release accompanying the consultation Health Secretary, Matt Hancock, stated, ‘For generations women have lived with a healthcare system that is mostly designed for men, by men’. Caroline Criado-Perez in her book “Invisible Women” captured multiple examples of how the world, including healthcare, is designed for men. Her book points out that as we move towards a world led by data, women are missing from the sources being used to inform those datasets. An article in the British Medical Journal (BMJ)1 in October 2020 found:

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has not recognised the need for specific, standalone guidelines on the inclusion of women, continuing to refer to women as a special subgroup to be considered when appropriate. Journals inconsistently publish sex disaggregated data on drug efficacy, safety, and toxicity, and industry rarely reports sex or gender differences on product labels. Fragmented action and resistance perpetuates and extends women's exclusion from timely, safe, and quality of life enhancing therapeutic options across their lives.

It would be a huge leap forward if the Health Strategy for England could improve the representation of women in pharmaceutical research. This is particularly pertinent now the pandemic has awoken governments to the public health and economic resilience strong data can provide. As countries turn to dealing with “long Covid”, the term for a range of longer-term health issues suffered by those who have had the virus, which seems to disproportionately effect women,2 more diverse clinical trials will be vital.

The Health Secretary’s decision to create a Women’s Health Strategy for England is the right one. It is even better that it seeks input from individual women and groups to inform how it develops through its public survey. What has become clear over the last year is that people from different backgrounds experience our public services differently. That experience cannot be represented and understood without seeking counsel from a broad range of service users.

The importance of getting this right also shouldn’t be underestimated. Earlier this year a report found black women are still four times more likely to die in childbirth or pregnancy than white women in the UK.3 The Eve Appeal, a charity for gynaecological cancers, found in a survey of healthcare professionals that 47% agreed that women not knowing the correct terminology for their reproductive anatomy could lead to delayed diagnosis of a gynaecological cancer.4 Menopausal women are now the fastest growing demographic in the workplace yet one in four considers leaving work due to the symptoms.5

This strategy isn’t just a nice to have, a way for the Government to appeal to women voters. Women are unnecessarily dying in childbirth or from cancers they were too embarrassed to discuss. Women are leaving the workforce because they don’t understand a natural though challenging part of ageing. All of this is bad for the economy and wider society. The pandemic has demonstrated in an all too clear manner how interconnected we all are in society. No woman or man is an island.

If this strategy can go some way to addressing problems in public services and public attitudes to women’s health, including in the workplace, then that will bring benefits to everyone. The mother who is alive to look after her child. The woman who survives because they caught her cancer early because she had the confidence and language to explain her symptoms. The woman who is supported by her employer through all of the life stages of womanhood. More effective medicines and medical interventions created because women were included in clinical trials.

The Women’s Health Strategy might be aimed at addressing long overdue issues for 51% of the population but 100% of society stands to benefit from it. It has never been a man’s world, let’s hope this strategy helps to shape our public services and society to reflect that fact.

[1] https://www.bmj.com/content/371/bmj.m3808
[2] https://swhr.org/long-covid-the-impact-on-women-and-ongoing-research/
[3] https://www.theguardian.com/global-development/2021/jan/15/black-women-in-the-uk-four-times-more-likely-to-die-in-pregnancy-or-childbirth
[4] https://eveappeal.org.uk/news-awareness/top-tips-for-talking-gynae/
[5] https://menopauseintheworkplace.co.uk/menopause-at-work/menopause-and-work-its-important

7th April 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications